VIDEO: Stelara induces remission, response ‘reassuring for our patients’ with IBD

In a Healio video exclusive, Maria T. Abreu, MD, outlined long-term data presented at the European Crohn’s and Colitis Congress on the use of Stelara among patients with inflammatory bowel disease.Results from the UNIFI study (n = 205 patients) showed ustekinumab (Stelara, Janssen) induced clinical response (80%), modified Mayo score response (79.5%), endoscopic improvement (67.3%) and clinical remission (58%). Further, among 171 patients who continued onto long-term extension, 95.9% achieved clinical response, 95.3% achieved modified Mayo score response, 80.7% showed endoscopicRead More

Generated by Feedzy